AZD6750 / Squamous Cell Carcinoma (skin) / Melanoma · Phase 1/2 Trial

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

ClinicalTrials.gov · August 19, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a prospective, early-phase safety and efficacy study of AZD6750 in patients with advanced or metastatic solid tumors, currently recruiting. No efficacy or safety results are available in this registry record; the trial is in active enrollment and no outcome data have been posted.

What was studied

Phase 1/2, Interventional, Non Randomized, Parallel, Open label, Treatment purpose. Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck…; age from 18 Years. Intervention: Module 1; Module 2. n = 120. 13 sites across 4 countries.

Key findings

Safety

Specific safety endpoints, inclusion/exclusion criteria details, and methodological features (e.g., blinding, randomization scheme) are not detailed in the registry.

Who this may help

Clinicians should monitor this trial for safety and efficacy signals as it progresses. No clinical recommendations can be made from this registry record, as no safety or efficacy data have been reported.

Plain-language summary

This is a Phase 1/2 trial registration with no results posted; the study is actively recruiting and designed to assess safety in a dose-escalation format across multiple solid tumor types.

Study design

As stated by the source record.

MethodsPrimary outcome measures: Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion) (assessed at Measured from the informed consent until Day 90 post-last dose.); Efficacy- Part 2B only (dose expansion) (assessed at Measured every 6 weeks for 48 weeks and every 12 weeks thereafter from first do…)

DesignPhase 1/2, Interventional, Non Randomized, Parallel, Open label, Treatment purpose

PopulationMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck…; age from 18 Years

Sample size120

InterventionModule 1; Module 2

Setting13 sites across 4 countries

Reported figures

Quoted from the source exactly as published.

Planned enrollment120

Trial phasePhase 1/2

Primary outcome measure (Safety)Safety assessed from informed consent through Day 90 post-last dose (Parts 1A, 2A, 2B)

Primary outcome measure (Efficacy)Efficacy assessed every 6 weeks for 48 weeks and every 12 weeks thereafter until disease progression or death (Part 2B only; approximately 2 years)

Clinical bottom line

Caveats

This is a registry record only; no results have been posted or reported.
Study is actively recruiting; enrollment and follow-up are incomplete.
Specific safety endpoints, inclusion/exclusion criteria details, and methodological features (e.g., blinding, randomization scheme) are not detailed in the registry.
No comparative control arm is described in the registry record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Phase 1/2 design with dose escalation and expansion cohorts; prospective and controlled.

Directness

strong

Directly measures safety in target population of advanced/metastatic solid tumor patients.

Consistency

insufficient

No results reported; consistency cannot be assessed from registry record alone.

Risk of bias

insufficient

Methodology details not provided in registry; blinding and allocation concealment not stated.

Sample adequacy

limited

Estimated 120 participants across multiple tumor types; modest for Phase 1/2 dose escalation.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07115043). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 120 participants (ESTIMATED). Conditions: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma. Interventions: DRUG: AZD6750; DRUG: rilvegostomig. Primary outcome measures: Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion) , Measured from the informed consent until Day 90 post-last dose.; Efficacy- Part 2B only (dose expansion) , Measured every 6 weeks for 48 weeks and every 12 weeks thereafter from first dose until disease progression or death in the absence of disease progression(approximately 2 years). Brief summary: A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

AZD6750Squamous Cell Carcinoma (skin)NCT07115043MelanomaAstraZenecaNon Small Cell Lung Cancer